Interleukin-1 Blockade in Recently Decompensated Heart Failure (RED-HART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01936909
Recruitment Status : Completed
First Posted : September 6, 2013
Results First Posted : December 22, 2017
Last Update Posted : December 22, 2017
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Anakinra (weeks 1-2) Drug: Anakinra (weeks 3-12) Drug: Placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study
Study Start Date : February 2014
Primary Completion Date : September 23, 2016
Study Completion Date : September 23, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Anakinra
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Anakinra (short)
Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Drug: Anakinra (weeks 1-2)
Anakinra 100 mg daily for weeks 1 and 2
Experimental: Anakinra (long)
Anakinra 100 mg daily for 12 weeks
Drug: Anakinra (weeks 1-2)
Anakinra 100 mg daily for weeks 1 and 2
Drug: Anakinra (weeks 3-12)
Other Name: Anakinra 100 mg daily for weeks 3 through 12
Placebo Comparator: Placebo
Placebo injections daily for 12 weeks
Drug: Placebo
Other Name: Placebo daily for week 1 through 12

Primary Outcome Measures :
  1. Interval Changes in Peak Oxygen Consumption (VO2) [ Time Frame: Baseline to 2 weeks ]
    Interval changes in peak oxygen consumption (VO2) after 2 weeks of anakinra treatment.

Secondary Outcome Measures :
  1. Quality of Life Improvement [ Time Frame: 12 weeks ]
    The Duke Activity Status Index questionnaire will be completed at enrollment and 12 weeks. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores represent increased ability to perform daily activities and may be interpreted as improved quality of life.

  2. Death or Hospital Admission for Heart Failure [ Time Frame: 24 weeks ]
    We will monitor survival and hospitalization for heart failure throughout the 24 week follow-up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 130 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All 6 criteria need to be met for enrollment of the patient in the study

  1. Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below:

    1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;
    2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);

      • pulmonary congestion/edema at physical exam OR chest X-Ray;
      • plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;
      • invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.
  2. The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction <50%) at most recent assessment by any imaging modality (within 12 months).
  3. The patient is now clinically stable and meets standard criteria for hospital discharge as documented by all the 3 conditions listed below:

    1. absence of dyspnea or pulmonary congestion/distress at rest;
    2. absence of pitting edema in the lower extremities, or in any other region;
    3. stable hemodynamic parameters (blood pressure, heart rate).
  4. The patient is of age ≥21 years old, and is willing and able to provide written informed consent.
  5. The patient is willing and able to comply with the protocol (i.e. self administration of the treatment, and exercise protocol).
  6. The patient has screening plasma C-reactive protein levels >2 mg/L.

Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.

  1. The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
  2. Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
  3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
  4. Previous or planned implantation of left ventricular assist devices or heart-transplant.
  5. Chronic use of intravenous inotropes.
  6. Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
  7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
  8. Active infection (of any type);
  9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
  10. Prior (within the past 10 years) or current malignancy.
  11. Any comorbidity limiting survival or ability to complete the study.
  12. End stage kidney disease requiring renal replacement therapy.
  13. Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
  14. Pregnancy.
  15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01936909

United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Antonio Abbate, MD, PhD Virginia Commonwealth University
Principal Investigator: Benjamin W Van Tassell, PharmD Virginia Commonwealth University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Virginia Commonwealth University Identifier: NCT01936909     History of Changes
Other Study ID Numbers: RED-HART (HM15339)
1R34HL117026 ( U.S. NIH Grant/Contract )
First Posted: September 6, 2013    Key Record Dates
Results First Posted: December 22, 2017
Last Update Posted: December 22, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents